Highest-materiality recent filing
Pliant Therapeutics Q1 net loss $20M; doses first patient in Phase 1b FORTIFY trial
Q1 net loss $20.0M vs $56.2M prior year; R&D expense $13.6M (down from $43.4M) due to bexotegrast termination and reduced headcount.
Directors David Pyott, Katharine Knobil, and Suzanne Bruhn will retire effective at the 2026 Annual Meeting; all departures are not due to any disagreements.
PLN-101095 Phase 1: 4 responders (1 CR, 3 PR) out of 10 secondary ICI-refractory patients; IFN-γ biomarker correlated with response.
Pliant Therapeutics CMO Éric Lefebvre to depart on Dec 15, 2025
Chief Medical Officer Éric Lefebvre's employment terminates effective Dec 15, 2025.
Pliant Therapeutics discontinues bexotegrast in IPF; Q2 net loss narrows to $43.3M
Bexotegrast development in IPF stopped due to unfavorable risk-benefit; full BEACON-IPF data to be published.
Pliant Therapeutics Q1 net loss $56.2M, cuts workforce 45% to extend cash runway
Net loss of $56.2M in Q1 2025 vs $47.0M prior-year; R&D expenses rose to $43.4M on BEACON-IPF close-out.
Pliant Therapeutics to cut 45% of workforce; CLO Mike Ouimette departs
Reduction impacts ~45% of current employees; expected to substantially complete by end of Q2 2025.
Pliant Therapeutics adopts limited-duration poison pill; rights expire March 11, 2026
Board adopted rights agreement on March 12, 2025; dividend of one right per share to holders of record March 25, 2025.
Pliant Therapeutics discontinues BEACON-IPF Phase 2b trial; reports Q4 2024 net loss of $49.7M
BEACON-IPF discontinued after DSMB and outside expert panel recommendation due to imbalance in IPF-related adverse events; early efficacy on FVC observed.
Pliant assembles outside expert panel to review bexotegrast trial after DSMB pause recommendation
DSMB recommended pause of enrollment and dosing in BEACON-IPF Phase 2b trial of bexotegrast in IPF.
Pliant Therapeutics pauses BEACON-IPF Phase 2b trial of bexotegrast after DSMB review
Voluntarily paused enrollment and dosing in BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF).
Pliant Therapeutics Q3 net loss $57.8M; BEACON-IPF enrollment on track for Q1 2025
Net loss of $57.8M vs $41.5M in Q3 2023; R&D expenses rose to $47.8M on BEACON-IPF trial.
Pliant Therapeutics Q2 net loss $55.9M; cash $438.1M; bexotegrast trials on track
Net loss $55.9M vs $41.2M prior year; R&D expense up to $45.6M driven by BEACON-IPF trial.
Pliant reports positive Phase 2a data for bexotegrast in PSC; 320 mg well tolerated up to 40 weeks
320 mg cohort met primary safety endpoint; no treatment-related severe or serious adverse events.
Bexotegrast 160 mg reduced total lung collagen on PET imaging vs. increased collagen on placebo over 12 weeks.
Pliant Therapeutics Q1 net loss $47.0M; bexotegrast adaptive Phase 2b/3 accelerated
Net loss $47.0M in Q1 2024 vs $37.5M in Q1 2023; R&D expenses rose to $37.1M from $29.3M.
BEACON-IPF trial implemented as pivotal, adaptive Phase 2b/3 design after EU and global health authority acceptance; expected to shorten late-stage development.
Pliant Therapeutics reports Q4 2023 net loss of $41.1M; positive bexotegrast data in PSC
Net loss $41.1M vs $35.1M YoY; R&D expenses $33.2M (+32% YoY) driven by bexotegrast costs.
Pliant reports positive Phase 2a data for bexotegrast 320 mg in PSC; fibrosis markers improved
Bexotegrast 320 mg well tolerated with no drug-related severe or serious adverse events; 96% of 27 patients completed 12 weeks.
Pliant Therapeutics reports Q3 net loss of $41.5M; positive bexotegrast PSC interim data
Net loss of $41.5M vs $30.6M in prior-year quarter; R&D expense $32.3M, G&A $15.3M.
Pliant Therapeutics reports positive Phase 2a INTEGRIS-PSC data for bexotegrast in PSC
Trial met primary safety endpoint; bexotegrast well tolerated with 94% completing 12 weeks, no drug-related SAEs.
Pliant Therapeutics Q1 net loss $37.5M; cash $577M; positive IPF 24-wk data
Q1 net loss $37.5M vs $28.1M YoY; R&D expense $29.3M, G&A $14.2M.
Bexotegrast 320 mg well tolerated up to 40 weeks; no drug-related serious adverse events.
Bexotegrast 320 mg in IPF Phase 2a showed statistically significant FVC increases at 12 weeks; no drug-related severe AEs.
Novartis terminates collaboration with Pliant; discontinues NASH program PLN-1474
Novartis notified Pliant on Feb 17, 2023 of termination of Collaboration and License Agreement, effective April 18, 2023.
Pliant Therapeutics launches $250M equity offering; prelim cash $331.2M
Preliminary cash, equivalents and short-term investments of $331.2M as of Dec 31, 2022 (unaudited).
Pliant Therapeutics: Bexotegrast 320 mg shows significant FVC increase in IPF Phase 2a trial
320 mg group met primary/safety endpoints; no drug-related severe/serious adverse events over 12 weeks.
Pliant Therapeutics Q3 loss $30.6M; positive Phase 2a IPF data; $215M offering closed
Net loss of $30.6M in Q3 2022 vs $27.0M prior year; cash & investments $360.2M, funding to mid-2025.
Pliant Therapeutics Q2 net loss $29.5M; pro-forma cash $379.8M after $215.7M offering
Net loss of $29.5M in Q2 2022 vs $22.8M in prior-year quarter; R&D expenses $26.3M (up from $19.2M).
Pliant Therapeutics raises ~$200M in public offering, reports preliminary cash of $163.6M
Preliminary cash, cash equivalents and short-term investments of $163.6M as of June 30, 2022.
Pliant Therapeutics reports positive Phase 2a data for PLN-74809 in IPF; FVC and QLF improved
INTEGRIS-IPF Phase 2a met primary and secondary endpoints; PLN-74809 well tolerated with no drug-related SAEs or discontinuations.
On May 1, 2025, the Company announced that in connection with the workforce reduction, the employment of Mike Ouimette, the Company’s Chief Legal and Compliance Officer and Corporate Secretary, would terminate effective May 1, 2025.
the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.
the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.
On November 16, 2022, Neil Exter, MBA, a member of the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) since 2015, notified the Board that he would retire from the Board and as a member of the Compensation Committee of the Board, in each case effective as of November 16, 2022.
the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, Dr. Katharine Knobil to fill a newly created Board seat
Max materiality 0.90 · Median 0.65 · Most common event other_material